FY2022 EPS Estimates for Vincerx Pharma, Inc. Boosted by B. Riley (NASDAQ:VINC)

Vincerx Pharma, Inc. (NASDAQ:VINC – Get Rating) – Analysts at B. Riley raised their FY2022 earnings per share (EPS) estimates for shares of Vincerx Pharma in a research report issued on Monday, April 11th. B. Riley analyst K. Patel now forecasts that the company will earn ($3.43) per share for the year, up from their prior estimate of ($3.88). B. Riley also issued estimates for Vincerx Pharma’s Q4 2022 earnings at ($0.79) EPS, FY2023 earnings at ($2.90) EPS, FY2024 earnings at ($2.68) EPS and FY2025 earnings at ($2.04) EPS.

Vincerx Pharma (NASDAQ:VINC – Get Rating) last released its quarterly earnings data on Tuesday, March 29th. The company reported ($0.31) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.00) by $0.69.

VINC has been the subject of several other research reports. Zacks Investment Research downgraded shares of Vincerx Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, February 22nd. HC Wainwright increased their price target on shares of Vincerx Pharma from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, March 29th. Cantor Fitzgerald assumed coverage on shares of Vincerx Pharma in a research report on Thursday, December 23rd. They set an “overweight” rating and a $25.00 price target for the company. SVB Leerink reduced their price target on shares of Vincerx Pharma from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, March 30th. Finally, Chardan Capital reduced their price target on shares of Vincerx Pharma from $30.00 to $14.00 in a research report on Wednesday, March 30th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $19.43.

Shares of VINC stock opened at $2.89 on Thursday. The firm has a 50-day moving average of $4.75 and a 200-day moving average of $9.04. The company has a market cap of $60.86 million, a P/E ratio of -1.27 and a beta of 1.16. Vincerx Pharma has a one year low of $2.86 and a one year high of $19.07.

A number of large investors have recently modified their holdings of the business. Royal Bank of Canada boosted its position in Vincerx Pharma by 390.1% during the third quarter. Royal Bank of Canada now owns 1,578 shares of the company’s stock worth $26,000 after purchasing an additional 1,256 shares during the period. Cubist Systematic Strategies LLC bought a new position in Vincerx Pharma during the third quarter worth about $25,000. Strs Ohio boosted its position in Vincerx Pharma by 172.7% during the third quarter. Strs Ohio now owns 3,000 shares of the company’s stock worth $48,000 after purchasing an additional 1,900 shares during the period. California State Teachers Retirement System boosted its position in Vincerx Pharma by 27.8% during the fourth quarter. California State Teachers Retirement System now owns 9,005 shares of the company’s stock worth $92,000 after purchasing an additional 1,958 shares during the period. Finally, Morgan Stanley boosted its position in Vincerx Pharma by 7.6% during the third quarter. Morgan Stanley now owns 34,751 shares of the company’s stock worth $562,000 after purchasing an additional 2,440 shares during the period. Hedge funds and other institutional investors own 79.54% of the company’s stock.

Vincerx Pharma Company Profile (Get Rating)

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies.

See Also